Neuroblastoma
📧 Sign up to get email alerts when something new happens for Neuroblastoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-01-10Clinical Trial Update: 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety [Phase 3]
Phase 3 clinical trial evaluating 18F-DOPA PET imaging for biodistribution and safety.
-
CLINICAL_TRIALS trial_result · 2021-10-19Clinical Trial Update: Oral Liquid 13-cis-retinoic Acid (13-CRA) [Phase 1, Phase 2]
Phase 1/2 trial of oral liquid 13-cis-retinoic acid (13-CRA) in neuroblastoma has completed; results posted.
-
CLINICAL_TRIALS trial_result · 2021-10-04Clinical Trial Update: Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma [Phase 2]
Phase II study of the monoclonal antibody ch14.18/CHO given by continuous infusion in patients with primary refractory or relapsed neuroblas…
-
CLINICAL_TRIALS trial_result · 2021-09-22Clinical Trial Update: Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT [Phase 2]
Phase 2 trial comparing Ga-DOTATOC PET sensitivity to Octreoscan SPECT+CT in medulloblastoma and related neuroendocrine tumors; results post…
-
CLINICAL_TRIALS trial_result · 2021-08-17Clinical Trial Update: A Phase I Trial of Anti-GD2 T-cells (1RG-CART) [Phase 1]
Phase I trial of anti-GD2 T-cells (1RG-CART) in relapsed or refractory neuroblastoma has completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-06-21Clinical Trial Update: A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma [Phase 1, Phase 2]
A Phase I/II study evaluating [124I]mIBG PET/CT in metastatic neuroblastoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-04-13Clinical Trial Update: Efficacy and Safety of Anlotinib, Irinotecan and Temozolomide in the Treatment of Refractory or Recurrent Neuroblastoma in Children: an Open, Single Arm, Single Center, Phase II Clinical Study [Phase 2]
Phase II open-label study evaluating the efficacy and safety of a combination of anlotinib, irinotecan, and temozolomide in children with re…
-
CLINICAL_TRIALS trial_result · 2021-02-02Clinical Trial Update: Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating the safety of 68Ga-DOTA-tyr3-Octreotide PET in diagnosing solid tumors has completed with posted results…
-
CLINICAL_TRIALS trial_result · 2021-01-22Clinical Trial Update: Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma [Phase 2]
Phase 2 trial investigating rituximab for opsoclonus–myoclonus associated with neuroblastoma; study terminated with posted results.
-
FDA approval · 2021-01-14FDA Approved: VINCRISTINE SULFATE — Supplemental Application (Hospira, Inc.)
The FDA approved a supplemental application filed by Hospira for vincristine sulfate, a generic vincristine product.
-
FDA approval · 2020-11-25FDA Approved: DANYELZA — Original Application (Y-mAbs Therapeutics, Inc.)
FDA approved DANYELZA (naxitamab) from Y-mAbs Therapeutics for pediatric patients with relapsed or refractory high-risk neuroblastoma confin…
-
CLINICAL_TRIALS trial_result · 2020-11-19Clinical Trial Update: 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating 4SCAR-T therapy targeting GD2, PSMA, and CD276 for neuroblastoma.
-
CLINICAL_TRIALS trial_result · 2020-10-29Clinical Trial Update: Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer [Phase 3]
Phase 3 trial comparing fixed versus flexible dosing of filgrastim to speed bone marrow recovery after chemotherapy in children; the study i…
-
CLINICAL_TRIALS trial_result · 2020-10-23Clinical Trial Update: High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) [Phase 3]
Phase 3 trial update for high-risk neuroblastoma in the SIOP-Europe (SIOPEN) study.
-
CLINICAL_TRIALS trial_result · 2020-10-06Clinical Trial Update: Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma [Phase 2]
Phase 2 trial update for a multimodal molecular targeted therapy in relapsed or refractory high-risk neuroblastoma.
-
FDA approval · 2020-09-29FDA Approved: UNITUXIN — Supplemental Application (United Therapeutics Corporation)
FDA granted approval of a supplemental application for Unituxin (dinutuximab) submitted by United Therapeutics Corporation.
-
CLINICAL_TRIALS trial_result · 2020-07-14Clinical Trial Update: Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2) [Phase 1, Phase 2]
Clinical trial update for long-term continuous infusion ch14.18/CHO plus subcutaneous Aldesleukin (IL-2) in Neuroblastoma (Phase 1/Phase 2).
-
CLINICAL_TRIALS trial_result · 2020-05-05Clinical Trial Update: Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma [Phase 1, Phase 2]
Clinical trial investigating crizotinib in children with relapsed or refractory solid tumors and anaplastic large cell lymphoma has complete…
-
CLINICAL_TRIALS trial_result · 2020-04-03Clinical Trial Update: Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission [Phase 2]
Phase 2 results of difluoromethylornithine (DFMO) used as a preventative therapy in high-risk neuroblastoma patients in remission; the trial…
-
CLINICAL_TRIALS trial_result · 2020-03-12Clinical Trial Update: High-Risk Neuroblastoma Chemotherapy Without G-CSF [NA]
A completed clinical trial examining high-risk neuroblastoma chemotherapy without G-CSF support; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-02-28Clinical Trial Update: Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma [NA]
Clinical trial update for anti-GD2 3F8 monoclonal antibody with GM-CSF in high-risk neuroblastoma; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-11-18Clinical Trial Update: Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma [Phase 2]
A phase 2 trial evaluating irinotecan hydrochloride and temozolomide with temsirolimus or dinutuximab in younger patients with refractory or…
-
CLINICAL_TRIALS trial_result · 2019-11-14Clinical Trial Update: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma [Phase 2]
Phase 2 trial evaluating 3F8/GM-CSF immunotherapy plus 13-cis-retinoic acid for consolidation in high-risk neuroblastoma; study terminated w…
-
CLINICAL_TRIALS trial_result · 2019-11-13Clinical Trial Update: Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma [Phase 2]
Phase 2 trial of bevacizumab, irinotecan, and temozolomide in relapsed or refractory neuroblastoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-11-12Clinical Trial Update: GA-68 DOTA-TOC of Somatostatin Positive Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial update for GA-68 DOTA-TOC targeting somatostatin receptors in neuroendocrine tumors and related malignancies, with …